0000000001252797

AUTHOR

M Clerico

showing 6 related works from this author

Discontinuation of treatment with Natalizumab after 24 courses. Report from spontaneous, observational, prospective study (TYSTOP).

2013

Multiple Sclerosis Natalizumab TySTOPSettore MED/26 - Neurologia
researchProduct

Neutralizing antibodies in multiple sclerosis patients treated with 375 microg interferon-beta-1b.

2009

Multiple sclerosis interferon-beta-1bSettore MED/26 - Neurologia
researchProduct

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related d…

2022

Abstract Background Multiple sclerosis (MS) is characterized by phenotypical heterogeneity, partly resulting from demographic and environmental risk factors. Socio-economic factors and the characteristics of local MS facilities might also play a part. Methods This study included patients with a confirmed MS diagnosis enrolled in the Italian MS and Related Disorders Register in 2000–2021. Patients at first visit were classified as having a clinically isolated syndrome (CIS), relapsing–remitting (RR), primary progressive (PP), progressive-relapsing (PR), or secondary progressive MS (SP). Demographic and clinical characteristics were analyzed, with centers’ characteristics, geographic macro-ar…

Multiple SclerosisCenters’ characteristics; Italian Multiple Sclerosis Register; Multiple sclerosis phenotypes; Real-world dataSettore MED/42 - Igiene Generale e ApplicataItalian Multiple Sclerosis RegisterDermatologyGeneral MedicineMultiple Sclerosis Chronic ProgressiveSettore MED/26Settore SECS-S/04 - DemografiaCenters’ characteristicsMultiple sclerosis phenotypeReal-world dataSettore MED/01 - Statistica MedicaPsychiatry and Mental healthMultiple Sclerosis Relapsing-RemittingPhenotypeRecurrenceHumansFemaleSettore MED/26 - NeurologiaNeurology (clinical)Centers’ characteristicReferral and ConsultationMultiple sclerosis phenotypes
researchProduct

TREATMENT CHOICE AFTER 24 NATALIZUMAB DOSES IN PATIENTS WITH MULTIPLE SCLEROSIS: A PROSPECTIVE OBSERVATIONAL STUDY, THE TY-STOP

2014

Multiple scleorsinatalizumabSettore MED/26 - Neurologia
researchProduct

The Italian multiple sclerosis register

2019

The past decade has seen extraordinary increase in worldwide availability of and access to several large multiple sclerosis (MS) databases and registries. MS registries represent powerful tools to provide meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments. Moreover, patients, physicians, industry, and policy makers have an active interest in real-world observational studies based on register data, as they have the potential to answer the questions that are most relevant to daily treatment decision-making. In 2014, the Italian MS Foundation, in collaboration with the Italian MS clinical centers, promoted and funded the creation of the …

Register (sociolinguistics)AdultMaleKnowledge managementDatabases FactualEpidemiologymedia_common.quotation_subjectDisease epidemiologyEpidemiology; Multiple sclerosis; Quality of care; RegisterLongitudinal StudieDermatologyNOCohort StudiesMultiple sclerosisDatabases03 medical and health sciences0302 clinical medicineMultiple SclerosiHumansQuality (business)Longitudinal Studies030212 general & internal medicineRegistriesEpidemiology Multiple sclerosis Quality of care Register Adult Cohort Studies Data Collection Databases Factual Female; Humans Italy; Longitudinal Studies Male Multiple Sclerosis RegistriesQuality of careFactualmedia_commonData collectionbusiness.industryData CollectionQuality of careCorrectionEpidemiology; Multiple sclerosis; Quality of care; Register; Adult; Cohort Studies; Data Collection; Databases Factual; Female; Humans; Italy; Longitudinal Studies; Male; Multiple Sclerosis; RegistriesGeneral MedicineRegisterItalyRegister dataPsychiatry and Mental HealthObservational studyOriginal ArticleSettore MED/26 - NeurologiaFemaleBusinessNeurology (clinical)Cohort Studie030217 neurology & neurosurgeryEpidemiology; Multiple sclerosis; Quality of care; Register; 2708; Neurology (clinical); Psychiatry and Mental Health2708Human
researchProduct

Looking for the best therapeutical stretegy after the 24th natalizumab adiministretion. The TY-STOP study

2012

natalizumab multiple sclerosis
researchProduct